Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$8.86 +2.0%	$7.79	$4.58 ▼ $9.48	$443.62M	1.88	532,534 shs	518,531 shs
ESPR Esperion Therapeutics	$2.22 +0.5%	$1.50	$0.69 ▼ $3.94	$447.60M	0.82	4.82 million shs	8.19 million shs
REPL Replimune Group	$5.40 +0.4%	$7.46	$2.68 ▼ $17.00	$421.52M	0.67	3.99 million shs	2.25 million shs
SKYE Skye Bioscience	$3.50 +0.6%	$3.76	$1.14 ▼ $7.11	$108.47M	2.21	648,097 shs	159,367 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	-0.91%	+2.24%	+14.95%	+43.40%	-0.46%
ESPR Esperion Therapeutics	+1.38%	+3.76%	+50.34%	+158.66%	+30.00%
REPL Replimune Group	-2.71%	-3.93%	+43.47%	-39.75%	-47.77%
SKYE Skye Bioscience	+0.58%	-1.97%	-3.60%	+74.17%	-42.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYRX CryoPort	3.729 of 5 stars	4.5	1.0	0.0	2.2	2.5	1.9
ESPR Esperion Therapeutics	3.7795 of 5 stars	3.4	1.0	3.9	2.5	1.7	0.6
REPL Replimune Group	3.9268 of 5 stars	3.1	2.0	4.5	1.8	2.5	0.6
SKYE Skye Bioscience	1.634 of 5 stars	3.6	2.0	0.0	1.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYRX CryoPort	3.00	Buy	$12.00	37.13% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	216.03% Upside
REPL Replimune Group	2.10	Hold	$6.50	21.50% Upside
SKYE Skye Bioscience	3.14	Buy	$15.50	345.40% Upside

Current Analyst Ratings Breakdown

Latest SKYE, REPL, ESPR, and CYRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
8/6/2025	CYRX CryoPort	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2025	CYRX CryoPort	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$15.00
8/6/2025	CYRX CryoPort	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$16.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	CYRX CryoPort	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYRX CryoPort	$228.38M	1.92	N/A	N/A	$9.53 per share	0.92
ESPR Esperion Therapeutics	$332.31M	1.34	$0.02 per share	90.73	($2.15) per share	-1.03
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYRX CryoPort	-$114.76M	$1.33	6.59	N/A	N/A	37.21%	-9.79%	-5.42%	11/6/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.49	N/A	N/A	N/A	-35.84%	-0.91%	-28.41%	11/6/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	11/11/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$1.06	N/A	N/A	N/A	N/A	-76.03%	-69.20%	N/A

Latest SKYE, REPL, ESPR, and CYRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
8/7/2025	Q2 2025	SKYE Skye Bioscience	-$0.34	-$0.44	-$0.10	-$0.44	N/A	N/A
8/5/2025	Q2 2025	CYRX CryoPort	-$0.20	-$0.29	-$0.09	$2.05	$41.74 million	$45.45 million
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	-$0.02	+$0.15	-$0.02	$62.55 million	$82.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYRX CryoPort	0.39	16.24	15.47
ESPR Esperion Therapeutics	N/A	1.15	0.76
REPL Replimune Group	0.21	6.94	6.94
SKYE Skye Bioscience	N/A	6.09	6.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYRX CryoPort	92.90%
ESPR Esperion Therapeutics	47.39%
REPL Replimune Group	92.53%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
CYRX CryoPort	10.00%
ESPR Esperion Therapeutics	1.70%
REPL Replimune Group	5.20%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYRX CryoPort	1,186	50.07 million	45.06 million	Optionable
ESPR Esperion Therapeutics	200	201.62 million	198.20 million	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable
SKYE Skye Bioscience	11	30.99 million	29.59 million	Optionable

SKYE, REPL, ESPR, and CYRX Headlines

Recent News About These Companies

Skye Bioscience to host KOL event on CBeyond Phase 2a clinical data readout

August 27 at 10:05 PM | msn.com

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

August 27 at 7:00 AM | globenewswire.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $15.50 Average PT from Analysts

August 25, 2025 | americanbankingnews.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts

August 24, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Major Shareholder 5Am Partners Vii, Llc Sells 60,956 Shares

August 23, 2025 | insidertrades.com

Skye Bioscience, Inc. to Present at Multiple Investment and Medical Conferences in September 2025

August 21, 2025 | quiverquant.comQ

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

August 21, 2025 | globenewswire.com

Skye Bioscience (NASDAQ:SKYE) Upgraded by Evercore ISI to Strong-Buy Rating

August 18, 2025 | marketbeat.com

Evercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform Recommendation

August 16, 2025 | msn.com

Evercore starts Skye Bioscience at Outperform on nimacimab potential

August 14, 2025 | msn.com

Skye Bioscience initiated with an Outperform at Evercore ISI

August 14, 2025 | msn.com

Skye Bioscience, Inc. (NASDAQ:SKYE) is Altium Capital Management LLC's 9th Largest Position

August 14, 2025 | marketbeat.com

Skye Bioscience Earnings Call: Positive Outlook Amid Challenges

August 13, 2025 | msn.com

Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform

August 9, 2025 | msn.com

Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...

August 9, 2025 | finance.yahoo.com

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

August 7, 2025 | globenewswire.com

We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully

August 6, 2025 | finance.yahoo.com

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

July 30, 2025 | globenewswire.com

SKYE Stock Price Quote | Morningstar

July 11, 2025 | morningstar.comM

Skye Bioscience, Inc. (SKYE) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SKYE, REPL, ESPR, and CYRX Company Descriptions

CryoPort NASDAQ:CYRX

$8.86 +0.17 (+1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$8.86 0.00 (-0.06%)

As of 07:02 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Esperion Therapeutics NASDAQ:ESPR

$2.22 +0.01 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$2.24 +0.01 (+0.68%)

As of 07:05 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Replimune Group NASDAQ:REPL

$5.40 +0.02 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$5.38 -0.02 (-0.37%)

As of 06:48 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Skye Bioscience NASDAQ:SKYE

$3.50 +0.02 (+0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$3.50 0.00 (0.00%)

As of 06:55 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time